Initial reporter occupation is patient/consumer.The meter and test strips were requested for investigation; however, the test strips in use at the time of the blood clots are no longer available.The meter and test strips from the time of the comparisons in jan and feb 2022 (lot 54974523) were provided for investigation where they were tested using retention controls.Testing results (qc range = 2.4 - 3.6 inr): qc 1: 2.9 inr, qc 2: 3.0 inr, and qc 3: 3.0 inr.The obtained qc values were in the allowed range of the used combination strip lot - qc lot.All measurements were without error messages.The results alleged by the customer were observed in the meter¿s patient result memory.On a regular basis, coaguchek strips of lots currently valid in the market are tested as part of routine retention testing and results have passed the internal inspection.Per product labeling, "coaguchek uses human recombinant thromboplastin.Therefore, the comparability to other human recombinant thromboplastins is best, whereas higher deviations can occur with other thromboplastins.However, those higher differences between thromboplastins of different (rabbit, bovine based) origin are not a coaguchek specific issue.Similar differences can be observed when a human recombinant thromboplastin-based laboratory method is compared against several other (rabbit, bovine-based) laboratory methods." the investigation did not identify a product problem.The cause of the event could not be determined.
|
On (b)(6) 17-feb-2022 we received an allegation that coaguchek xs meter serial number (b)(4) using strip lot 54974523 with expiration date 31-jan-2023 was not reading correctly when compared to an unknown laboratory method in (b)(6) 2022 and (b)(6) 2022.It was reported that the patient's therapeutic range used to be 2.5 - 3.5 inr but due to blood clots allegedly occurring in (b)(6) 2021 and (b)(6) 2021, the patient's therapeutic range was reportedly increased to 3.0 - 3.5 inr.The first alleged blood clot was identified on (b)(6) 2021 and the second alleged blood clot was identified on 08-sep-2021.The test strip lot number used in sep-2021 and oct-2021 was not known.This medwatch will cover the second alleged blood clot identified on (b)(6) 2021.Refer to medwatch with patient identifier (b)(6) for information on the first alleged blood clot identified on (b)(6) 2021 and medwatch with patient identifier (b)(6) for the meter to lab comparison results from (b)(6) 2022 and (b)(6) 2022.The meter results prior to the blood clot on 04-oct-2021: on 22-sep-2021 the meter result was 4.6 inr.The patient believes her warfarin dose was changed but does not know what change was made.On 29-sep-2021 the meter result was 4.2 inr.On 04-oct-2021 the alleged second clot was identified.The laboratory result at this time was reportedly 3.2 inr.The patient reportedly starting taking aspirin after the 2nd blood clot.On 08-oct-2021 the meter result was 3.9 inr.The patient's warfarin dose is reportedly based on the meter results unless there is a lab result available from the same day.If a lab result is available from the same day, the patient's warfarin dose is reportedly adjusted based on the laboratory results.The patient could not remember what specific adjustments were made prior to the blood clot in (b)(6) 2021.On 16-dec-2021 the patient had another tee scope performed and the shadowing observed before was reportedly gone.The patient reportedly used to test once per week, but, has "had to test more frequently at times due to the issues she has had.".
|